Henovcom will participate in the 5th mRNA-Based Therapeutics Summit in Boston, USA.?The COO, Junlan Ren, will deliver a presentation titled “Novel Efficient Cap Analog and Rapidly Eliminated Ionizable Lipid Improve the Efficacy and Safety of mRNA-Based Protein Replacement Therapy,” and will also participate in poster session.
To shine light on emerging areas and the latest progress, the 5th mRNA-Based Therapeutics Summit returns to Boston as the world's largest, end-to-end mRNA conference, gathering 320+ global stakeholders, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA, Circular RNA & Self-Amplifying RNA fields including Moderna, Pfizer, BioNTech, Grann Pharmaceuticals, Celestial Therapeutics, Byterna Therapeutics and more.
Topic: Novel Efficient Cap Analog and Rapid Eliminated Ionizable Lipid Improve the Efficacy and Safety of mRNA Based Protein Replacement Therapy
Date: Tuesday 22th July 2025
Time: 14:30-15:00 (GMT-4)
Speaker: Junlan Ren
??????? ? ??Co-founder &?COO
Key points:
mRNAs formulated with LZCap? exhibit superior in vivo pharmacokinetics for protein translation across multiple species, including rats, beagle dogs, pigs, and cynomolgus monkeys.
The novel ionizable lipid-based LNPs deliver high transfection efficiency with rapid in vivo clearance and a favorable safety profile.
Preclinical studies of the protein replacement pipeline demonstrate robust efficacy and excellent tolerability.?
